Symposium 230
STATE-OF-THE-ART MANAGEMENT OF IBD: CURRENT REALITIES AND FUTURE HORIZONS
SESSION III: New generation diagnostics
Chairs: Matthieu Allez, Paris; Fernando Gomollón, Zaragoza
Duration: 106 min
Extracellular RNAs and other markers as potential noninvasive liquid biopsy biomarkers in IBD
Bram Verstockt, Leuven
Intestinal ultrasonography – extended clinical exam for all IBD clinicians?
Torsten Kucharzik, Lueneburg
Endoscopy in IBD: How will artificial intelligence help us in the future?
Marietta Iacucci, Birmingham
The future of radiology for IBD
Andrea Laghi, Rome
©Falk Foundation e.V., Freiburg. All rights reserved.
Combination therapy with golimumab and guselkumab for ulcerative colitis (VEGA): Data from a phase 2 proof-of-concept study suggest that combination therapy with guselkumab and golimumab may be more effective for ulcerative colitis than therapy with either drug alone.
Etrasimod as induction and maintenance therapy for ulcerative colitis: The S1P receptor modulator etrasimod was more effective than placebo in two phase 3 trials and well tolerated in patients with moderately to severely active ulcerative colitis.
Combination therapy with trifluridine-tipiracil (FTD-TPI) and bevacizumab in colorectal cancer: Combination therapy resulted in longer overall survival than FTD-TPI alone in a phase 3 trial among patients with refractory metastatic colorectal cancer.
Antiviral therapy for hepatitis B virus (HBV) infection in cirrhosis: A recent study suggests that antiviral therapy of low-level viremia (HBV DNA < 2000 IU/ml) may not reduce the risk of decompensation or hepatocellular carcinoma (HCC).
Risk assessment in non-alcoholic fatty liver disease (NAFLD): The fibrosis 4 (FIB4) score allows a simple risk assessment of patients with low (FIB4 < 1.3) or high (FIB4 > 2.67) risk of cirrhosis. A current cohort study identifies diabetes status and PNPLA3-rs738409 genotype as suitable risk assessment for patients with indeterminate FIB4 score (FIB4 1.3–2.67).
Liver resection for hepatocellular carcinoma (HCC) in patients with metabolic syndrome: A recent study demonstrates that patients with metabolic syndrome who undergo liver resection for HCC are at high risk for postoperative serious complications and death. Careful patient selection considering baseline characteristics, liver function and type of surgery is possible using a new online model: https://childb.shinyapps.io/NomogramMajorMorbidity90days.
Efficacy and safety of drugs for gastroparesis: In a network meta-analysis, oral dopamine antagonists and tachykinin-1 antagonists were more efficacious than placebo, but confidence in the evidence was low to moderate for most comparisons.
Drainage of large pancreatic walled-off necroses (WON) using plastic versus lumen-apposing metal stents (LAMS): Drainage of large WON (> 15 cm) using LAMS with a diameter of 20 mm was not superior to conventional plastic stents in this randomized monocenter trial. Both approaches were associated with comparable needs for necrosectomy and hospital stay without gross differences in adverse events.
Symposium 234
Mucosal Immunology – A Translational View into the Clinic
July 6 – 8, 2023, Potsdam
Dorint Hotel Sanssouci, Jägerallee 20, 14469 Potsdam, Germany
Symposium
Workshop: Orphan Diseases in Hepatology and Gastroenterology
November 2, 2023, 08:30 – 18:30 Uhr, Madrid
Hotel Meliá Castilla Calle del Poeta Joan Maragall, 43, 28020 Madrid, Spain
Symposium 235
Therapeutic Update in GI-disease
November 3 – 4, 2023, Madrid
Hotel Meliá Castilla Calle del Poeta Joan Maragall, 43, 28020 Madrid, Spain